Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans.

Vyas, K P; Halpin, R A; Geer, L A; Ellis, J D; Liu, L; Cheng, H; Chavez-Eng, C; Matuszewski, B K; Varga, S L; Guiblin, A R; Rogers, J D

Vyas, K P; Halpin, R A; Geer, L A; Ellis, J D; Liu, L; Cheng, H; Chavez-Eng, C; Matuszewski, B K; Varga, S L; Guiblin, A R; Rogers, J D.

Affiliation

Vyas KP; Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486, USA. kamlesh_vyas@merck.com

Drug Metab Dispos ; 28(1): 89-95, 2000 Jan.

Article in En | MEDLINE | ID: mdl-10611145

Subject(s)

Serotonin Receptor Agonists/pharmacokinetics; Triazoles/pharmacokinetics; Administration, Oral; Area Under Curve; Carbon Radioisotopes/metabolism; Chromatography, High Pressure Liquid; Cross-Over Studies; Feces; Humans; Infusions, Intravenous; Male; Migraine Disorders/drug therapy; Reference Values; Serotonin Receptor Agonists/administration & dosage; Serotonin Receptor Agonists/therapeutic use; Serotonin Receptor Agonists/urine; Tissue Distribution; Triazoles/administration & dosage; Triazoles/therapeutic use; Triazoles/urine; Tryptamines

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Triazoles / Serotonin Receptor Agonists Type of study: Clinical_trials / Prognostic_studies Limits: Humans / Male Language: En Journal: Drug Metab Dispos Journal subject: FARMACOLOGIA Year: 2000 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links